

Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-4 (canceled)

Claim 5 (currently amended): An immunogenic composition comprising,
(a) an immunogenic peptide fragment of fibroblast growth factor wherein the immunogenic peptide consists of a heparin binding domain of fibroblast growth factor, ~~peptide wherein said peptide fragment does not consist of SEQ ID NO:2~~; and
(b) a pharmaceutically acceptable carrier.

Claim 6 (previously presented): The composition of Claim 5, wherein the amino acid sequence of the immunogenic peptide consists of SEQ ID NO: 1.

Claim 7 (previously presented): The composition of Claim 5, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

Claim 8 (original): The composition of Claim 7, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L- amino acids.

Claim 9 (original): The composition of Claim 7, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

Claim 10 (original): The composition of Claim 9, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's

complete adjuvant, polydispersed β -(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

Claim 11 (previously presented): The composition of Claim 5, further comprising a hydrophobic moiety attached to the immunogenic peptide.

Claim 12 (original): The composition of Claim 11, wherein the hydrophobic moiety comprises at least one long chain fatty acid having at least 10 carbon atoms in the lipid backbone.

Claim 13 (original): The composition of Claim 11, wherein the hydrophobic moiety is selected from the group consisting of palmitic acid, stearic acid, myristic acid, lauric acid, oleic acid, linoleic acid, and linolenic acid.

Claim 14 (canceled)

Claim 15 (previously presented): An immunogenic composition comprising,

- (a) an immunogenic peptide fragment of vascular endothelial growth factor wherein the immunogenic peptide fragment consists of a receptor binding domain of vascular endothelial growth factor;
- (b) wherein the immunogenic peptide fragment consists of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8 or SEQ ID NO: 9; and
- (c) a pharmaceutically acceptable carrier.

Claim 16 (canceled)

2
1
Claim 17 (previously presented): The composition of Claim 15, wherein the pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

3
2
Claim 18 (original): The composition of Claim 17, wherein the carrier protein comprises maltose binding protein, bovine serum albumin, keyhole limpet hemocyanin, ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and polymers of D- and/or L- amino acids.

4
2
Claim 19 (original): The composition of Claim 17, further comprising adjuvants, preservatives, diluents, emulsifiers, and stabilizers.

5
4
Claim 20 (original): The composition of Claim 19, wherein the adjuvant is selected from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers, aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's complete adjuvant, polydispersed β -(1,4) linked acetylated mannan, polyoxyethylene-polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella pertussis*, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

6
1
Claim 21 (previously presented): The composition of Claim 15, further comprising a hydrophobic moiety attached to the immunogenic peptide.

7
6
Claim 22 (original): The composition of Claim 21, wherein the hydrophobic moiety comprises at least one long chain fatty acid having at least 10 carbon atoms in the lipid backbone.

8
6
Claim 23 (original): The composition of Claim 21, wherein the hydrophobic moiety is selected from the group consisting of palmitic acid, stearic acid, myristic acid, lauric acid, oleic acid, linoleic acid, and linolenic acid.

Claim 24 (canceled)

Claim 25 (previously presented) An immunogenic composition comprising,
(a) an immunogenic peptide fragment of fibroblast growth factor and
vascular endothelial growth factor, wherein the immunogenic
peptide fragment of fibroblast growth factor consists of a heparin
binding domain and wherein the immunogenic peptide fragment of
vascular endothelial growth factor consists of a receptor binding
domain; and
(b) a pharmaceutically acceptable carrier.

Claim 26 (previously presented) The composition of Claim 25, wherein the
pharmaceutically acceptable carrier comprises liposomes, colloidal gold, and carrier proteins.

Claim 27 (original): The composition of Claim 26, wherein the carrier protein
comprises maltose binding protein, bovine serum albumin, keyhole limpet hemocyanin,
ovalbumin, flagellin, thyroglobulin, serum albumin, gamma globulin, syngeneic cells, and
polymers of D- and/or L- amino acids.

Claim 28 (original): The composition of Claim 26, further comprising adjuvants,
preservatives, diluents, emulsifiers, and stabilizers.

Claim 29 (original): The composition of Claim 28, wherein the adjuvant is selected
from the group consisting of lipophilic muramyl dipeptide derivatives, nonionic block polymers,
aluminum hydroxide, aluminum phosphate, lipid A, Freund's incomplete adjuvant, Freund's
complete adjuvant, polydispersed β -(1,4) linked acetylated mannan, polyoxyethylene-
polyoxypropylene copolymer adjuvants, saponin derivative adjuvants, killed *Bordetella*

pertussis, lipopolysaccharide of gram-negative bacteria, polymeric anions, dextran sulfate, inorganic gels, alum, aluminum hydroxide, and aluminum phosphate.

Claims 30-49 (canceled)

Claim 50 (original): An immunogenic composition comprising,

- (a) An immunogenic peptide fragment of vascular endothelial growth factor wherein the immunogenic peptide fragment consists of a receptor binding domain of vascular endothelial growth factor, and immunogenic fragments of said immunogenic peptide
- (b) wherein the immunogenic peptide fragment consists of SEQ ID NO: 6, and
- (c) a pharmaceutically acceptable carrier.

2102004 >